Skip to main content
Elanix Biotechnologies AG logo

Elanix Biotechnologies AG — Investor Relations & Filings

Ticker · ELN ISIN · DE000A0WMJQ4 LEI · 391200SYNFFL0NPAJK90 F Manufacturing
Open in API
Filings indexed 161 across all filing types
Latest filing 2017-09-20 Regulatory Filings
Country DE Germany
Listing F ELN

About Elanix Biotechnologies AG

https://elanixbiotechnologies.com/

Elanix Biotechnologies AG is a tissue regeneration company that develops and commercializes products for acute wound care, dermatological, and gynecological applications. The company's core focus is on creating therapeutic solutions derived from progenitor cells. Its product development pipeline aims to provide advanced treatments for skin and tissue repair.

Recent filings

Filing Released Lang Actions
Elanix Biotechnologies Subsidiary Signs Wholesale & Logistics Agreement in Europe to Support Expanding Commercialization of GYNrepair(R)
Regulatory Filings Classification · 100% confidence The document is a 'PRESS RELEASE' disseminated via DGAP-News, dated September 20, 2017. It announces a specific business event: a subsidiary signing a 'Wholesale & Logistics Agreement in Europe' to support commercialization. This is not a full financial report (like 10-K or IR), an earnings release (ER), or a formal regulatory filing like a proxy statement or director's dealing. It is a corporate announcement regarding business operations and strategy execution. Since it is a general corporate news item that doesn't fit the highly specific categories like M&A (TAR), Capital Change (CAP), or Dividend (DIV), it falls best under the general 'Regulatory Filings' category, which serves as a fallback for miscellaneous corporate news announcements distributed via regulatory channels (like DGAP). Given the length (5198 chars) and content, it is the announcement itself, not a notice *about* an attached report.
2017-09-20 English
Elanix Biotechnologies AG: Annual General Meeting resolves cash capital increase with preemptive rights at a subscription ratio of 4:1
AGM Information Classification · 98% confidence The document is an 'Ad-hoc' announcement dated August 24, 2017, detailing resolutions passed at the 'Annual General Meeting' (AGM). Specifically, it reports on the resolution for a 'cash capital increase with pre-emptive rights'. While it mentions the AGM, the core subject is a corporate action related to capital structure (a capital increase). This aligns best with the 'Capital/Financing Update' category (CAP). Although it references the AGM, the primary focus is the financial/capital event, not the general AGM presentation (AGM-R) or the voting results (DVA). Given the explicit mention of 'Capital Increase' and the nature of the announcement, CAP is the most precise fit.
2017-08-24 English
ELANIX BIOTECHNOLOGIES AG STARTS DUE DILIGENCE TO ACQUIRE A FETAL PROGENITOR BONE CELL LINE WITHIN A CAPITAL INCREASSE BY WAY OF CONTRIBUTION IN KIND
Share Issue/Capital Change Classification · 99% confidence The document is an 'Ad-hoc' announcement dated August 22, 2017, disclosing inside information according to Article 17 MAR. The core subject is the company starting due diligence to acquire another entity ('Swiss Inno 4 Cell AG') through a 'capital increase by way of contribution in kind'. This action directly relates to changes in the company's structure, financing, and assets, which falls under Capital/Financing Update (CAP). While it mentions an upcoming AGM, the primary focus is the proposed transaction structure (contribution in kind within a capital increase), making CAP the most specific fit over AGM-R or a general regulatory filing.
2017-08-22 English
Elanix Biotechnologies AG: Elanix Biotechnologies's Partner Transwell Biotech Starts First Clinical Study with Progenitor Cell Treatment for Skin Graft Wounds
Regulatory Filings Classification · 99% confidence The document is a press release dated July 20, 2017, announcing that Elanix Biotechnologies' partner has started the first clinical study (Phase I/II) for a progenitor cell treatment (TWB-103) for skin graft wounds. It details the study objectives, locations, and quotes from management. This type of announcement, focusing on clinical trial progress and partnership updates, is typically classified as a general corporate news release or an update on business operations, rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial event like a dividend (DIV) or capital change (CAP). Since it is a specific business update that doesn't fit the highly specialized categories (like DIRS, NAV, DEF 14A), and it is not a short announcement pointing to a separate report (RPA), the most appropriate general category for significant corporate news that isn't strictly financial reporting is often captured under Regulatory Filings (RNS) as a general announcement, or sometimes Investor Presentation (IP) if it were a presentation, but here it is a news release about operational progress. Given the options, and that it is a news announcement about clinical progress, it fits best as a general Regulatory Filing/News announcement (RNS) or potentially a general corporate update if a more specific category existed. Since it is a news release about operational progress, RNS serves as the best fit among the provided codes for non-standard, material corporate news.
2017-07-20 English
Elanix Biotechnologies AG: Bekanntmachung der Einberufung zur Hauptversammlung am 24.08.2017 in Berlin mit dem Ziel der europaweiten Verbreitung gema 121 AktG
AGM Information Classification · 99% confidence The document is titled 'Einladung zur ordentlichen Hauptversammlung' (Invitation to the Annual General Meeting) and explicitly mentions the date and location of the meeting (24. August 2017 in Berlin). The agenda items (Tagesordnung) include the presentation of annual financial statements, discharge of board members, election of supervisory board members, and proposed changes to the articles of association regarding remuneration and authorized capital. This content is characteristic of materials distributed for an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R.
2017-07-18 German
Elanix Biotechnologies AG: Vorstand und Aufsichtsrat schlagen der ordentlichen Hauptversammlung 2017 eine Bar-Kapitalerhohung um bis zu 50% mit mittelbarem Bezugsrecht vor
Capital/Financing Update Classification · 98% confidence The document is an 'Ad-hoc' announcement dated July 13, 2017, from Elanix Biotechnologies AG. The core subject is the proposal by the Management Board and Supervisory Board to the Annual General Meeting (Hauptversammlung) for a cash capital increase ('Bar-Kapitalerhöhung') of up to 50%. This announcement explicitly mentions the upcoming 'ordentlichen Hauptversammlung 2017' (Annual General Meeting 2017) and details a proposed resolution regarding capital structure changes (capital increase). This directly relates to corporate financing activities and capital structure changes, fitting the 'Capital/Financing Update' (CAP) category. While it mentions the AGM, the primary focus is the capital proposal, not the AGM materials themselves (AGM-R) or the voting results (DVA). It is a proposal for a capital action.
2017-07-13 German

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.